Free Trial
NASDAQ:XBIT

XBiotech (XBIT) Stock Price, News & Analysis

XBiotech logo
$6.38 +0.04 (+0.63%)
(As of 12/20/2024 05:17 PM ET)

About XBiotech Stock (NASDAQ:XBIT)

Key Stats

Today's Range
$6.13
$6.66
50-Day Range
$6.09
$8.25
52-Week Range
$3.81
$9.96
Volume
214,749 shs
Average Volume
76,925 shs
Market Capitalization
$194.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Receive XBIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter.

XBIT Stock News Headlines

This is the worst sign for the U.S. stock market in 50 years
The Dow recently posted its worst losing streak since 1974. And one of America's most accurate analysts now says this is just the beginning of a new crisis that could be worse than the COVID crash, the dot-com crash, and even the Great Depression. Introducing "The Dead Zone"
XBiotech Inc. (XBIT)
See More Headlines

XBIT Stock Analysis - Frequently Asked Questions

XBiotech's stock was trading at $4.00 at the beginning of the year. Since then, XBIT stock has increased by 59.5% and is now trading at $6.38.
View the best growth stocks for 2024 here
.

XBiotech (XBIT) raised $76 million in an IPO on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO.

Top institutional investors of XBiotech include Geode Capital Management LLC (1.48%), UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC (0.83%), State Street Corp (0.74%) and Connor Clark & Lunn Investment Management Ltd. (0.25%).
View institutional ownership trends
.

Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that XBiotech investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and AUO (AUOTY).

Company Calendar

Today
12/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:XBIT
Employees
100
Year Founded
N/A

Profitability

Net Income
$-24,560,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$4.01 million
Book Value
$7.19 per share

Miscellaneous

Free Float
20,393,000
Market Cap
$194.48 million
Optionable
Optionable
Beta
1.41

Social Links

Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

This page (NASDAQ:XBIT) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners